Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study
Sara Khan,Palma Solano-Paez,Tannu Suwal,Mei Lu,Salma Al-Karmi,Ben Ho,Iqra Mumal,Mary Shago,Lindsey M Hoffman,Andrew Dodgshun,Sumihito Nobusawa,Uri Tabori,Ute Bartels,David S Ziegler,Jordan R Hansford,Vijay Ramaswamy,Cynthia Hawkins,Christelle Dufour,Nicolas André,Eric Bouffet,Annie Huang,Rare Brain Tumor Registry,Almeida Gonzalez Cv,Derek Stephens,Sarah Leary,Paula Marrano,Adriana Fonseca,Nirav Thacker,Bryan K Li,Holly B Lindsay,Alvaro Lassaletta,Anne E Bendel,Christopher Moertel,Andres Morales La Madrid,Vicente Santa-Maria,Cinzia Lavarino,Eloy Rivas,Sebastian Perreault,Benjamin Ellezam,Alexander G Weil,Nada Jabado,Angelica Oviedo,Michal Yalon-Oren,Laura Amariglio,Helen Toledano,Rina Dvir,James Loukides,Timothy E Van Meter,Hideo Nakamura,Tai-Tong Wong,Kuo-Sheng Wu,Chien-Jui Cheng,Young-Shin Ra,Milena La Spina,Luca Massimi,Anna Maria Buccoliero,Alyssa Reddy,Rong Li,G Yancey Gillespie,Dariusz Adamek,Jason Fangusaro,David Scharnhorst,Joseph Torkildson,Donna Johnston,Jean Michaud,Lucie LafayCousin,Jennifer Chan,Frank Van Landeghem,Beverly Wilson,Sandra Camelo-Piragua,Nabil Kabbara,Mahjouba Boutarbouch,Derek Hanson,Chad Jacobsen,Karen Wright,Rajeev Vibhakar,Jean M Levy,Yin Wang,Daniel Catchpoole,Nicholas Gerber,Michael A Grotzer,Violet Shen,Ashley Plant,Christopher Dunham,Maria Joao Gil da Costa,Ramya Ramanujachar,Eric Raabe,Jeffery Rubens,Joanna Phillips,Nalin Gupta,Haci Ahmet Demir,Christine Dahl,Mette Jorgensen,Eugene I Hwang,Roger J Packer,Amy Smith,Enrica Tan,Sharon Low,Jian-Qiang Lu,Ho-Keung Ng,Jesse L Kresak,Sridharan Gururangan,Scott L Pomeroy,Nongnuch Sirachainan,Suradej Hongeng,Vanan Magimairajan,Roona Sinha,Naureen Mushtaq,Reuben Antony,Mariko Sato,David Samuel,Michal Zapotocky,Samina Afzal,Andrew Walter,Tarik Tihan,Derek S Tsang,Amar Gajjar,Paul Wood,Jason E Cain,Peter A Downie,Nicolas Gottardo,Helen Branson,Suzanne Laughlin,Birgit Ertl-Wagner,Abhaya V Kulkarni,Michael D Taylor,James Drake,George M Ibrahim,Peter B Dirks,James T Rutka,Gino R Somers,Lili-Naz Hazrati,Franck Bourdeaut,Laetitia Padovani,Richard G Grundy,Claire M Mazewski,Maryam Fouladi
DOI: https://doi.org/10.1016/S2352-4642(21)00245-5
Abstract:Background: Embryonal tumours with multi-layered rosettes (ETMRs) are a newly recognised, rare paediatric brain tumour with alterations of the C19MC microRNA locus. Due to varied diagnostic practices and scarce clinical data, disease features and determinants of outcomes for these tumours are poorly defined. We did an integrated clinicopathological and molecular analysis of primary ETMRs to define clinical phenotypes, and to identify prognostic factors of survival and key treatment modalities for this orphan disease. Methods: Paediatric patients with primary ETMRs and tissue available for analyses were identified from the Rare Brain Tumor Consortium global registry. The institutional histopathological diagnoses were centrally re-reviewed as per the current WHO CNS tumour guidelines, using histopathological and molecular assays. Only patients with complete clinical, treatment, and survival data on Nov 30, 2019, were included in clinicopathological analyses. Among patients who received primary multi-modal curative regimens, event-free survival and overall survival were determined using Cox proportional hazard and log-rank analyses. Univariate and multivariable Cox proportional hazard regression was used to estimate hazard ratios (HRs) with 95% CIs for clinical, molecular, or treatment-related prognostic factors. Findings: 159 patients had a confirmed molecular diagnosis of primary ETMRs (median age at diagnosis 26 months, IQR 18-36) and were included in our clinicopathological analysis. ETMRs were predominantly non-metastatic (94 [73%] of 128 patients), arising from multiple sites; 84 (55%) of 154 were cerebral tumours and 70 (45%) of 154 arose at sites characteristic of other brain tumours. Hallmark C19MC alterations were seen in 144 (91%) of 159 patients; 15 (9%) were ETMR not otherwise specified. In patients treated with curative intent, event-free survival was 57% (95% CI 47-68) at 6 months and 31% (21-42) at 2 years; overall survival was 29% (20-38) at 2 years and 27% (18-37) at 4 years. Overall survival was associated with non-metastatic disease (HR 0·48, 95% CI 0·28-0·80; p=0·0057) and non-brainstem location (0·42 [0·22-0·81]; p=0·013) on univariate analysis, as well as with gross total resection (0·30, 0·16-0·58; p=0·0014), high-dose chemotherapy (0·35, 0·19-0·67; p=0·0020), and radiotherapy (0·21, 0·10-0·41; p<0·0001) on multivariable analysis. 2-year event-free and overall survival was 0% at 2 years in patients treated with conventional chemotherapy without radiotherapy (regardless of surgery extent), and 21% (95% CI 1-41) and 30% (6-54), respectively, in patients treated with high-dose chemotherapy, and gross total resection without radiotherapy. 2-year event-free survival in patients treated with high-dose chemotherapy and radiotherapy was 66% (95% CI 39-93) for patients with gross total resection and 44% (7-81) for patients with sub-total resection. 2-5-year overall survival was 66% (95% CI 33-99, p=0·038) for patients with gross total resection and 67% (36-98, p=0·0020) for patients with sub-total resection. Interpretation: Prompt molecular diagnosis and post-surgical treatment with intensive multi-modal therapy tailored to patient-specific risk features could improve ETMR survival. Funding: Canadian Institute of Health Research, Canada Research Chair Awards, Australian Lions Childhood Cancer Research Foundation, Spanish Society of Pediatrics, Consejería de Salud y Familias de la Junta de Andalucía, Miracle Marnie, Phoebe Rose Rocks, Tali's Funds, Garron Cancer Centre, Grace's Walk, Meagan's Hug, Brainchild, Nelina's Hope, and Jean Martel Foundation.